A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511744-27-00

Acronym

CLN-619-001

Enrollment

240

Registered

2024-03-29

Start date

2022-06-27

Completion date

2025-12-29

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer, Cervical Cancer, Endometrial Cancer, gastrointestinal cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026